Epidemiology and survival outcomes of HIV-associated cervical cancer in Nigeria.

IF 3.1 2区 医学 Q3 IMMUNOLOGY
Jonah Musa, Masha Kocherginsky, Francis A Magaji, Ali J Maryam, Joyce Asufi, Danjuma Nenrot, Kirsten Burdett, Neelima Katam, Elizabeth N Christian, Nisha Palanisamy, Olukemi Odukoya, Olugbenga A Silas, Fatimah Abdulkareem, Philip Akpa, Kabir Badmos, Godwin E Imade, Alani S Akanmu, Demirkan B Gursel, Yinan Zheng, Brian T Joyce, Chad J Achenbach, Atiene S Sagay, Rose Anorlu, Jian-Jun Wei, Folasade Ogunsola, Robert L Murphy, Lifang Hou, Melissa A Simon
{"title":"Epidemiology and survival outcomes of HIV-associated cervical cancer in Nigeria.","authors":"Jonah Musa, Masha Kocherginsky, Francis A Magaji, Ali J Maryam, Joyce Asufi, Danjuma Nenrot, Kirsten Burdett, Neelima Katam, Elizabeth N Christian, Nisha Palanisamy, Olukemi Odukoya, Olugbenga A Silas, Fatimah Abdulkareem, Philip Akpa, Kabir Badmos, Godwin E Imade, Alani S Akanmu, Demirkan B Gursel, Yinan Zheng, Brian T Joyce, Chad J Achenbach, Atiene S Sagay, Rose Anorlu, Jian-Jun Wei, Folasade Ogunsola, Robert L Murphy, Lifang Hou, Melissa A Simon","doi":"10.1186/s13027-023-00550-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Invasive cervical cancer (ICC) is an HIV-associated cancer that is preventable and precancerous stages including early ICC stages could be detected through screening offering opportunities for treatment and cure. The high incidence in women living with HIV and late presentation often at advanced stages of ICC with limited treatment facilities often result in early mortality. We sought to compare the epidemiologic characteristics and survival differences in HIV status of ICC patients in Nigeria.</p><p><strong>Methods: </strong>We conducted a cohort study at two federal academic hospital-based research sites in Jos University Teaching Hospital, and Lagos University Teaching Hospital Nigeria, between March 2018 and September 2022. We enrolled women with histologically confirmed ICC with known HIV status, and FIGO staging as part of the United States of America's National Institutes of Health/National Cancer Institute funded project titled 'Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria'. The primary outcome was all-cause mortality with assessment of overall survival (OS) and time to death after ICC diagnosis. OS distribution was estimated using the method of Kaplan-Meier and compared between groups using the log-rank test.</p><p><strong>Results: </strong>A total of 239 women with confirmed ICC were enrolled and included in this analysis, of whom 192 (80.3%) were HIV-negative (HIV-/ICC +), and 47 (19.7%) were HIV-positive (HIV +/ICC +). The HIV +/ICC + patients were younger with median age 46 (IQR: 40-51) years compared to 57 (IQR: 45-66) among HIV-/ICC + (P < 0.001). Squamous cell carcinoma was the commonest histopathologic variant in 80.4% of ICC diagnosis, moderately differentiated tumor grade in 68.1% in both groups. HIV +/ICC + diagnosis was at FIGO advanced stages in 64.9% compared to 47.9% in HIV-/ICC +. The HIV-/ICC + women had better OS compared to HIV +/ICC + participants (p = 0.018), with 12-month OS 84.1% (95%CI 75-90%) and 67.6% (95%CI 42-84%) respectively.</p><p><strong>Conclusion: </strong>ICC is diagnosed at a relatively young age in women living with HIV, with a significantly lower overall survival probability compared to women without HIV. The trend of presentation and diagnosis at advanced stages in women living with HIV could partly explain the differences in overall survival.</p>","PeriodicalId":13568,"journal":{"name":"Infectious Agents and Cancer","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619301/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Agents and Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13027-023-00550-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Invasive cervical cancer (ICC) is an HIV-associated cancer that is preventable and precancerous stages including early ICC stages could be detected through screening offering opportunities for treatment and cure. The high incidence in women living with HIV and late presentation often at advanced stages of ICC with limited treatment facilities often result in early mortality. We sought to compare the epidemiologic characteristics and survival differences in HIV status of ICC patients in Nigeria.

Methods: We conducted a cohort study at two federal academic hospital-based research sites in Jos University Teaching Hospital, and Lagos University Teaching Hospital Nigeria, between March 2018 and September 2022. We enrolled women with histologically confirmed ICC with known HIV status, and FIGO staging as part of the United States of America's National Institutes of Health/National Cancer Institute funded project titled 'Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria'. The primary outcome was all-cause mortality with assessment of overall survival (OS) and time to death after ICC diagnosis. OS distribution was estimated using the method of Kaplan-Meier and compared between groups using the log-rank test.

Results: A total of 239 women with confirmed ICC were enrolled and included in this analysis, of whom 192 (80.3%) were HIV-negative (HIV-/ICC +), and 47 (19.7%) were HIV-positive (HIV +/ICC +). The HIV +/ICC + patients were younger with median age 46 (IQR: 40-51) years compared to 57 (IQR: 45-66) among HIV-/ICC + (P < 0.001). Squamous cell carcinoma was the commonest histopathologic variant in 80.4% of ICC diagnosis, moderately differentiated tumor grade in 68.1% in both groups. HIV +/ICC + diagnosis was at FIGO advanced stages in 64.9% compared to 47.9% in HIV-/ICC +. The HIV-/ICC + women had better OS compared to HIV +/ICC + participants (p = 0.018), with 12-month OS 84.1% (95%CI 75-90%) and 67.6% (95%CI 42-84%) respectively.

Conclusion: ICC is diagnosed at a relatively young age in women living with HIV, with a significantly lower overall survival probability compared to women without HIV. The trend of presentation and diagnosis at advanced stages in women living with HIV could partly explain the differences in overall survival.

Abstract Image

Abstract Image

Abstract Image

尼日利亚HIV相关宫颈癌症的流行病学和生存结果。
简介:侵袭性宫颈癌症(ICC)是一种与HIV相关的癌症,是可以预防的,包括早期ICC阶段在内的癌前阶段可以通过筛查发现,为治疗和治愈提供机会。感染艾滋病毒的妇女发病率高,而且往往在ICC晚期晚期出现,治疗设施有限,往往导致早期死亡。我们试图比较尼日利亚ICC患者的流行病学特征和HIV状态的生存差异。方法:2018年3月至2022年9月,我们在乔斯大学教学医院和尼日利亚拉各斯大学教学医院的两个联邦学术医院研究点进行了一项队列研究。作为美国国立卫生研究院/国立癌症研究所资助的题为“尼日利亚HIV-相关癌症的表观基因组生物标志物”的项目的一部分,我们招募了具有组织学确诊ICC的已知HIV状态和FIGO分期的女性。主要结果是全因死亡率,并评估ICC诊断后的总生存率(OS)和死亡时间。OS分布使用Kaplan-Meier方法估计,并使用对数秩检验在各组之间进行比较。结果:共有239名确诊为ICC的女性被纳入本分析,其中192人(80.3%)为HIV阴性(HIV/ICC +), 47人(19.7%)为HIV阳性(HIV +/ICC +). 艾滋病毒 +/ICC + 患者更年轻,中位年龄46岁(IQR:40-51),而HIV/ICC患者中位年龄57岁(IQR:45-66) + (P 结论:感染艾滋病毒的妇女在相对年轻的时候就被诊断为ICC,与未感染艾滋病毒的女性相比,其总体生存概率明显较低。艾滋病毒感染妇女晚期表现和诊断的趋势可以部分解释总生存率的差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Infectious Agents and Cancer
Infectious Agents and Cancer ONCOLOGY-IMMUNOLOGY
CiteScore
5.80
自引率
2.70%
发文量
54
期刊介绍: Infectious Agents and Cancer is an open access, peer-reviewed online journal that encompasses all aspects of basic, clinical, epidemiological and translational research providing an insight into the association between chronic infections and cancer. The journal welcomes submissions in the pathogen-related cancer areas and other related topics, in particular: • HPV and anogenital cancers, as well as head and neck cancers; • EBV and Burkitt lymphoma; • HCV/HBV and hepatocellular carcinoma as well as lymphoproliferative diseases; • HHV8 and Kaposi sarcoma; • HTLV and leukemia; • Cancers in Low- and Middle-income countries. The link between infection and cancer has become well established over the past 50 years, and infection-associated cancer contribute up to 16% of cancers in developed countries and 33% in less developed countries. Preventive vaccines have been developed for only two cancer-causing viruses, highlighting both the opportunity to prevent infection-associated cancers by vaccination and the gaps that remain before vaccines can be developed for other cancer-causing agents. These gaps are due to incomplete understanding of the basic biology, natural history, epidemiology of many of the pathogens that cause cancer, the mechanisms they exploit to cause cancer, and how to interrupt progression to cancer in human populations. Early diagnosis or identification of lesions at high risk of progression represent the current most critical research area of the field supported by recent advances in genomics and proteomics technologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信